Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation - Test2 - elhamkhani - TriplyDB

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

http://www.wikidata.org/entity/Q28250054

about

Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysis Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century Nerve agent exposure elicits site-specific changes in protein phosphorylation in mouse brain Nicotine receptor partial agonists for smoking cessation Pharmacological interventions for promoting smoking cessation during pregnancy Nicotine receptor partial agonists for smoking cessation Pharmacological interventions for promoting smoking cessation during pregnancy Nicotine receptor partial agonists for smoking cessation Innate C-H trifluoromethylation of heterocycles Unravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptors Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis Nicotine binding to brain receptors requires a strong cation-pi interaction Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence Orthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking Cessation Bacoside A: Role in Cigarette Smoking Induced Changes in Brain Molecules and circuits involved in nicotine addiction: The many faces of smoking Preclinical evidence that activation of mesolimbic alpha 6 subunit containing nicotinic acetylcholine receptors supports nicotine addiction phenotype Rational development of addiction pharmacotherapies: successes, failures, and prospects Improvement of restless legs syndrome by varenicline as antismoking treatment Enantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective α4β2-nAChR Ligands.Structural Characterization of Binding Mode of Smoking Cessation Drugs to Nicotinic Acetylcholine Receptors through Study of Ligand Complexes with Acetylcholine-binding Protein Molecular actions of smoking cessation drugs at 4 2 nicotinic receptors defined in crystal structures of a homologous binding protein Targeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.Nicotinic receptor modulation to treat alcohol and drug dependence Emerging drugs for the treatment of tobacco dependence: 2014 update The role of the habenula in drug addiction.An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles Functional probes of drug-receptor interactions implicated by structural studies: Cys-loop receptors provide a fertile testing ground Prescription drugs associated with reports of violence towards others Mechanisms of inhibition and potentiation of α4β2 nicotinic acetylcholine receptors by members of the Ly6 protein family Impact of physical exercise on substance use disorders: a meta-analysis Nicotinic Activity of Arecoline, the Psychoactive Element of "Betel Nuts", Suggests a Basis for Habitual Use and Anti-Inflammatory Activity Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial Varenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatum Conductance of P2X4 purinergic receptor is determined by conformational equilibrium in the transmembrane region nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Treatment of nicotine addiction: present therapeutic options and pipeline developments.Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use?

P2860

Q21254640-BAC8D654-E5DC-45F2-88BF-A548E7700557 Q22305613-6EE7C590-8714-4856-AB9D-8A252B086058 Q23913649-84225A44-8538-4BB0-8DD3-34D64C7C1AF5 Q24185773-4FB817EA-F423-481E-8E5C-F2901B37DFB8 Q24186969-B714E348-C8D9-4B2C-A6CF-6946F67FD4B5 Q24200322-86A2251A-D7B8-4C9F-961A-7895E64847F3 Q24200435-7DA3EF37-AA06-4BB8-AA75-581436F03EE7 Q24235456-3B9A4E9D-48B3-4C95-B442-4F9A374EF6D7 Q24603689-5361EB3B-7743-4F64-BE99-6165ACBD2F1B Q24634426-A34BD7D3-DC35-428B-9BC5-64B052F9D721 Q24634536-077ECD01-C7A3-4531-AF0B-A028979D619F Q24641901-6C5AE0DD-3D37-4B88-BCD0-8E386109632A Q26751374-5CA52EF9-3277-45DA-8618-458FFD96223D Q26774830-C1461A62-9E2C-44B8-BCE7-82FA017298F4 Q26786019-837D5747-EC23-471A-9666-DEECEEED308C Q27008063-8F0B1ED3-D628-4271-A040-0FB1E0C34487 Q27021772-262D9936-43C8-4138-AE65-E3DADF545775 Q27025533-1087903A-F1D3-43D4-9EE7-4C5C6037596D Q27025687-AAD8C706-FC53-4104-A88E-42CC0A283CB8 Q27335322-B048A351-C1D1-4CEF-B513-AEDFC176CEC8 Q27678875-C3060060-B070-4A6B-A3D5-EF76C8227EC7 Q27679259-E9BC8A0F-0DA8-4567-86E8-92C127DF474C Q27693356-CA283F7C-C17E-4E0B-9FDF-F93C198D3A6B Q28087047-AB3023C4-F252-45B2-8CB5-9D82CE471620 Q28236453-44BA318C-C7F3-4657-81EA-D76FE8908B34 Q28238267-23322953-E6E8-4B9F-8817-5A9180501992 Q28301501-67B0483D-87CA-4587-9AB4-80011297CED0 Q28307979-57172901-91AE-4CBB-9A9A-4DF208D93DD5 Q28476532-CF7D489E-0DFC-42D7-89B9-96CCFB13C5B1 Q28509139-9A94A39F-4D77-4E21-807E-8F85BA31E27A Q28543880-5554D6D7-F73C-4AEB-B2A1-4918565342FB Q28550433-8D033FE3-0AAB-48D4-84DD-ABA742824010 Q28552053-68C385E5-E726-440D-B5A7-D702782E4B51 Q28576280-23684A15-5EB0-4D7E-91F0-A81C326E2760 Q28833615-1180AC83-0A07-42C4-BB2F-5FF43A954EC3 Q30362464-F78C3C34-0B46-4220-A7AC-6F789E943EB6 Q30396291-17AA0EA3-5BEE-4E38-AB2B-F42F14768FDD Q30398847-97C34286-30AC-40EA-8840-EBF8D56CF182 Q30433175-EB885B7C-A986-43A6-9EEA-2260F3E696E3 Q30441131-DDF509A6-4ECD-45AE-B8EA-4A747E1219E3

P2860

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

http://www.wikidata.org/entity/Q28250054

description

2005 nî lūn-bûn

@nan

2005 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

@ast

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

@en

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

@nl

type

label

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

@ast

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

@en

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

@nl

prefLabel

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

@ast

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

@en

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

@nl

P1433

Q28250054-D55015B2-638D-4DA9-92E8-BDF3185A737F

P1476

Q28250054-6B277C10-AFBF-42BC-8B04-78198BA4BB68

P2093

Q28250054-0FC62F80-468E-4689-95FB-05F7C569B6DB

Q28250054-105DDFD7-3117-405A-94D2-79BDE0FF2249

Q28250054-14EE84C3-163C-491C-A919-EBD92187FBE7

Q28250054-1D603E65-8B28-439D-9821-A5052FF5DCB7

Q28250054-2ED722C1-BCDF-4755-88D3-0F77F9F8CFEC

Q28250054-2FD69275-C12E-4095-B168-CA9A8542BA20

Q28250054-3601FEF6-28A8-4340-863A-7160B42BD8C0

Q28250054-39FC6896-383D-404F-83B0-969589B5DE5F

Q28250054-405ACC73-F056-4000-B501-5621566FEBD6

Q28250054-4B541E08-8BB0-443D-B932-CFBD11CF8711

P304

Q28250054-0FB81ECC-32D7-4D42-B44B-6ED087CE9CAA

P31

Q28250054-E696E768-DF9D-47E3-BD79-8B9CFDAFA49F

P3181

Q28250054-D47307F6-5612-49DA-9897-93D60A9701D2

P356

Q28250054-92F76183-6317-4129-978C-7492CCCA15DF

P407

Q28250054-151B572F-778B-4AAF-A3BF-7A0A236ABB5A

P433

Q28250054-C9260AEF-AD57-4F6B-B587-71565CF308D8

P478

Q28250054-C70D037A-09C9-4007-AA79-6897F2E8EF57

P577

Q28250054-C8F78776-9716-42D0-8799-CD8FEF47F73F

P5875

Q28250054-63A1C491-C6DB-4865-BCF2-2AA0F8BF5CD4

P698

Q28250054-8F396B7E-D903-4391-94C0-3613DEB7F1FA

P921

Q28250054-27744E3C-C6F1-4D0A-9E6D-02F71E045AB8

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation

@en

P2093

Alka Shrikhande

http://www.w3.org/2001/XMLSchema#string

Brian T O'Neill

http://www.w3.org/2001/XMLSchema#string

Carol B Fox

http://www.w3.org/2001/XMLSchema#string

Charles C Rovetti

http://www.w3.org/2001/XMLSchema#string

David W Schulz

http://www.w3.org/2001/XMLSchema#string

Eric P Arnold

http://www.w3.org/2001/XMLSchema#string

Eric Schaeffer

http://www.w3.org/2001/XMLSchema#string

F David Tingley

http://www.w3.org/2001/XMLSchema#string

Hans Rollema

http://www.w3.org/2001/XMLSchema#string

James H Heym

http://www.w3.org/2001/XMLSchema#string

P304

3474-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2660444

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM050069N

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2005-05-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7853230

http://www.w3.org/2001/XMLSchema#string

P698

15887955

http://www.w3.org/2001/XMLSchema#string

P921